Poly Medicure Limited
NSE: POLYMEDMarket Closed • NSE
Day range
52 week range
Poly Medicure Limited closed at INR1593.80 (+0.63%) on volume 0.48x its 20-day average, trading 23.9% below its 52-week high.
2026-Q1
Q1 FY2026 Financial Results
PAT moved -8.3% QoQ
2026-08-28
DIVIDEND Announced
Dividend - Rs 3.50 Per Share
2025-09-18
DIVIDEND Announced
Dividend - Rs 3.50 Per Share
Revenue and PAT bars use independent scales to make their year-on-year direction readable.
Complete reported financial history · Values use the company's reporting currency
Hover over the chart for exact reported values. Percentage lines use the right-hand axis.
A 0–100 quantitative summary of reported fundamentals. Use the underlying financials and risks for context; the score is not a buy or sell recommendation.
Strengths
Low Debt Profile: Debt-to-Equity is comfortable at 0.11x
Risks
Stretched Valuation: Trading at a high P/E multiple of 51.3x
Bull case
Market Leadership: Established operational scale in Medical Instruments & Supplies.
Bear case
Macro Headwinds: Fluctuations in interest rates and sector-specific policy shifts could compress multiples.
Flip condition
Sustained quarterly EBITDA margin expansion above 20% would trigger an upgrade.
Complete dividend, bonus, split, rights and other action history
| Record date | Corporate action | Information | Announcement date | Ex-date |
|---|---|---|---|---|
| 29 Aug 2026 | Dividend | ₹3.50 / share | — | 28 Aug 2026 |
| 18 Sept 2025 | Dividend | ₹3.50 / share | — | 18 Sept 2025 |
| — | Dividend | ₹3.00 / share | — | 19 Sept 2024 |
| — | Dividend | ₹3.00 / share | — | 21 Sept 2023 |
| — | Dividend | ₹2.50 / share | — | 16 Sept 2022 |
| 17 Sept 2021 | Dividend | ₹2.50 / share | — | 16 Sept 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 16 Sept 2021 |
| — | Annual General Meeting | Annual General Meeting | — | 21 Sept 2020 |
| 29 Feb 2020 | Dividend | ₹2.00 / share | — | 27 Feb 2020 |
| — | Dividend | ₹2.00 / share | — | 13 Sept 2019 |
| — | Dividend | ₹2.00 / share | — | 18 Sept 2018 |
| — | Dividend | ₹0.50 / share | — | 20 Sept 2017 |
| 28 Mar 2017 | Bonus issue | 1:1 bonus ratio | — | 24 Mar 2017 |
| 16 Feb 2017 | Dividend | ₹1.00 / share | — | 15 Feb 2017 |
| 15 Nov 2016 | Dividend | ₹1.00 / share | — | 11 Nov 2016 |
| — | Dividend | ₹0.50 / share | — | 19 Sept 2016 |
| 18 Mar 2016 | Dividend | ₹2.50 / share | — | 17 Mar 2016 |
| — | Dividend | ₹2.50 / share | — | 18 Sept 2015 |
| 03 Feb 2015 | Dividend | ₹10.00 / share | — | 02 Feb 2015 |
Traded volume and delivery percentage across the latest 20 sessions
Compare valuation, latest quarterly performance and year-on-year growth
| Company name | Market cap ₹ Cr | P/E ratio | Dividend yield % | Quarterly sales ₹ Cr | Profit after tax ₹ Cr | Sales growth % | Profit growth % |
|---|---|---|---|---|---|---|---|
 Sun Pharmaceutical Industries LimitedSUNPHARMA Open analysis | ₹4.22L | 34.90 | 0.91% | ₹15,300.00 | ₹2,901.00 | +10.46% | +26.52% |
 Divi's Laboratories LimitedDIVISLAB Open analysis | ₹2.43L | 82.97 | 0.33% | ₹3,080.00 | ₹902.00 | +27.80% | +65.50% |
 Torrent Pharmaceuticals LimitedTORNTPHARM Open analysis | ₹1.73L | 72.83 | 0.83% | ₹4,128.00 | ₹389.00 | +41.90% | -21.89% |
 Apollo Hospitals Enterprise LimitedAPOLLOHOSP Open analysis | ₹1.13L | 54.32 | 0.25% | ₹7,044.00 | ₹610.00 | +20.58% | +38.32% |
 Zydus Lifesciences LimitedZYDUSLIFE Open analysis | ₹1.12L | 25.03 | 0.09% | ₹8,017.00 | ₹990.00 | +21.95% | -34.91% |
 LENSKART SOLUTIONS LTDLENSKART Open analysis | ₹1.12L | 174.73 | 0.00% | ₹2,714.00 | ₹228.00 | +43.29% | +273.77% |
 Laurus Labs LimitedLAURUSLABS Open analysis | ₹1.11L | 101.83 | 0.12% | ₹2,026.31 | ₹367.60 | +29.10% | +125.49% |
 Cipla LimitedCIPLA Open analysis | ₹1.07L | 31.78 | 0.98% | ₹7,119.00 | ₹786.00 | +2.33% | -39.16% |
Poly Medicure Limited engages in the manufacture and sale of medical devices in India and internationally. The company offers infusion therapy products, such as I.V Infusion set, extension lines, needle free connector, I.V flow regulator extension set, burette set, three way stop cock, vial access spike, transfer spike, orburator, polyflush, maifolds, polyswab, and arterial blood collection; critical care products, including vial access spikes, arterial cannula, mini mid lines over the wire, extension line, enteral connector, central venous catheters, and huber needle; dialysis and renal care products, comprising peritoneal dialysis set, haemocent, standard and safety fistula needle, dialyzer, bloodlines and dialysis system. It also provides cardiology products PTFE wire, inflation device, Y-connector, manifold, introducer, IV Cannula, hydrophilic wire, guiding catheter, drug eluting stent, PTCA dilation catheter, diagnostic catheter, and electrocardiograph electrodes; vaccular access products; oncology products; diagnostics products, such as blood collection tubes, safety blood collection set, blood collection needles, and standard needle holder. In addition, the company offers transfusion system products, including blood bags, blood administration set, and others; anesthesia and respiratory care products, comprising variable concentration masks, oxygen mask with reservoirs, fixed concentration masks, aerosol therapy masks, ventilator circuits, suction catheters, spinal needle, polyciser, oxygen catheter, nebulizer compressor system, twin bore nasal oxygen cannula mucus extractor, HME filter, oro-pharyngeal airways, endotracheal tubes, catheter mount, and brain circuit; urology products, including urine collection bags, leg bag set, irrigation sets, foley balloon and urine drainage catheters, and urine collection bags with measured volume meters; wound drainage; and gastroenterology products. The company was incorporated in 1995 and is based in New Delhi, India.
IndiaHealthcare
Is Poly Medicure Limited Shariah compliant?
Poly Medicure Limited is currently screened as Shariah Compliant under AAOIFI Shariah Standard No. 21. Business activities align with Shariah permissible sectors. Debt to Market Cap (2.19%) complies with AAOIFI threshold (≤ 33%).
What is Poly Medicure Limited's current valuation relative to peers?
Poly Medicure Limited trades at a P/E of 51.3x compared to the sector median of 37x, and a Price-to-Book of 5.2x.
Is the company financially healthy?
The company has a Debt-to-Equity ratio of 0.11x. Interest coverage is 17.9x.
What are the historical revenue and profit growth rates?
Over the past 5 years, revenue compounded at steady rates while net profit growth averaged consistent levels.
Market data is informational and may be delayed. Shariah screening follows the displayed methodology. This is not investment advice.
Market data may be delayed. Quote date: 2026-10-16. Financial figures relate to their stated reporting periods. This information is for research and is not a recommendation to buy or sell.